Navigation Links
ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter
Date:4/13/2011

expects to execute through its 50 plus partner hospital network sites.

Located in the U.S. and India, TotipotentSC serves as the exclusive distributor for Res-Q and MXP™ MarrowXpress™ in India, Malaysia, Thailand and Mauritius for all fields of use except the human orthopedic market, which is non-exclusive, and is the Company's non-exclusive distributor in South Africa for all fields of use. In these regions, TotipotentSC supports clinical progress in the stem cell field through specialized product and service support.  

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

  • The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP® AutoXpress™ Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP™ MarrowXpress™ and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
  • The Res-Q™ 60 BMC (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates.
  • The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The Cryo
    '/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Major China Regenerative Medicine Company Adopts ThermoGenesis Cord Blood Stem Cell Processing And Storage Technologies
2. ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China
3. ThermoGenesis Announces Agreement for AXP and BioArchive Cord Blood Systems With Major Chinese Stem Cell Company
4. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2011 Results on February 10, 2011
5. ThermoGenesis Corp. and TotipotentSC Receive Approval for Phase Ib Clinical Trial of Res-Q™ 60 BMC for Treatment of Critical Limb Ischemia
6. ThermoGenesis Corp. Files Shelf Registration Statement on Form S-3
7. ThermoGenesis Signs Major Bone Marrow Product Distribution Agreement in China
8. ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
9. ThermoGenesis Corp. to Announce First Quarter Fiscal 2011 Results on November 4, 2010
10. ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement
11. ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Computerized tomographic (CT),colonography, also known as virtual colonoscopy, ... flexible tube with a camera to view the,lining ... detect cancer and,precancerous polyps and could serve as ... the results of the American College of,Radiology Imaging ...
... Department of,Justice announced today that it will not ... (CRC) to develop and publicize model contract language,for ... Department said,the language is not likely to be ... in contract negotiations, potentially reducing costs,and shortening the ...
Cached Medicine Technology:Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 2Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 3Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 4Justice Department Will Not Oppose CEO Roundtable on Cancer's Proposal 2
(Date:4/18/2014)... one of your worst memories? How did it make ... during a negative personal experience, such as how sad ... to emotional distress, especially when you can,t stop thinking ... up, thinking about the context of the memories, rather ... effective way to alleviate the negative effects of these ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... Hepatitis ... C Relapsers and Nonresponders, KENILWORTH, N.J., Nov. 15 ... European Commission on,October 30 approved 48-week standard-dose PEGINTRON(TM) (peginterferon,alfa- 2b, ... mg,daily) combination therapy for retreating adult patients with chronic,hepatitis C ...
... largely on children entering school ready to learn, and ... children for school entry. A new study finds that ... for school, suggesting that intervention could help boost readiness ... Laval University, the University of Montreal, and the University ...
... some prescriptions , , WEDNESDAY, Nov. 14 (HealthDay News) -- ... allow certain drugs to be sold by pharmacists without ... to arguments for and against the proposal by representatives ... at the day,s end, the FDA officials said they ...
... Response Genetics, Inc.,(Nasdaq: RGDX ) a company ... cancer, today announced its consolidated financial results for,the ... September 30, 2007. "The third quarter of ... physician and investment communities," said Kathleen Danenberg,President and ...
... Dragon Pharmaceutical Inc.,(TSX: DDD; OTC BB: DRUG; BBSE: ... and nine months ended September 30, 2007, showing ... antibiotic business. Meanwhile,the Company also announced the sale ... a separate press release. Highlights for the ...
... Holdings, Inc. (the,"Company") today announced its operating results for ... Three Months Ended September 30, 2007 Net Revenues ... for the three months,ended September 30, 2007, increased by ... Patient days increased by 289 during the 2007 period.,During ...
Cached Medicine News:Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 2Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 3Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 4Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 5Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 6Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 7Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 8Health News:Environment plays key role in children's readiness for school 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 4Health News:Response Genetics Reports Third Quarter 2007 Financial Results 2Health News:Response Genetics Reports Third Quarter 2007 Financial Results 3Health News:Response Genetics Reports Third Quarter 2007 Financial Results 4Health News:Response Genetics Reports Third Quarter 2007 Financial Results 5Health News:Response Genetics Reports Third Quarter 2007 Financial Results 6Health News:Response Genetics Reports Third Quarter 2007 Financial Results 7Health News:Response Genetics Reports Third Quarter 2007 Financial Results 8Health News:Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 2Health News:Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 3Health News:Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 4Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 2Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 3Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 4Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 5Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 6Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 7Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 8Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 9Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 10Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 11Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 12Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 13Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 14Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 15
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: